Ülke: Yeni Zelanda
Dil: İngilizce
Kaynak: Medsafe (Medicines Safety Authority)
Propranolol hydrochloride 40mg
Ipca Pharma (NZ) Pty Limited
Propranolol hydrochloride 40 mg
40 mg
Tablet
Active: Propranolol hydrochloride 40mg Excipient: Sunset Yellow FCF Aluminium lake Cl15985 Brilliant Blue FCF Aluminium lake Cl42090 Lactose monohydrate Magnesium stearate Maize starch Povidone Quinoline yellow Sodium starch glycolate
Prescription
Ipca Laboratories Limited
Management of angina pectoris.
Package - Contents - Shelf Life: Bottle, White HDPE bottle with white polypropylene child resistant cap - 100 tablets - 36 months from date of manufacture stored at or below 25°C protect from light
2014-06-27
NEW ZEALAND DATA SHEET Please refer to Medsafe website (www.medsafe.govt.nz) for the most recent datasheet Page 1 of 9 1. PRODUCT NAME IPCA-PROPRANOLOL 10 MG AND 40 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION EACH TABLET CONTAINS 10 MG OR 40 MG PROPRANOLOL HYDROCHLORIDE Chemical Structure: Chemical Name: 2-propanol, 1-[(1-methyl-ethyl)amino]-3-(1-naphthalenyloxy), hydrochloride, (±). Molecular Formula: C 16 H 21 NO 2 ,HCl Molecular Weight: 295.8 CAS Registry Number: 318-98-9. EXCIPIENT(S) WITH KNOWN EFFECT : LACTOSE. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM IPCA-PROPRANOLOL 10mg tablets :Orange coloured, round, biconvex tablets, embossed with "P" and "10" on either side of the breakline on one side and plain on the other side. IPCA-PROPRANOLOL 40 mg tablets: Green coloured, round, biconvex tablets, embossed with "P" and "40" on either side of the breakline on one side and plain on the other side. The score line is not intended for breaking the tablet 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Management of angina pectoris. • Long term prophylaxis after recovery from acute myocardial infarction. • Control of most forms of cardiac dysrhythmias. • Control of essential and renal hypotension • Prophylaxis of migraine. • Control of anxiety and anxiety tachycardia • Management of essential tremor. • Adjunctive management of thyrotoxicosis and thyrotoxic crisis. • Management of hypertrophic obstructive cardiomyopathy. • Management of phaeochromocytoma (with an alpha-adrenoreceptor blocking medicine). NEW ZEALAND DATA SHEET Please refer to Medsafe website (www.medsafe.govt.nz) for the most recent datasheet Page 2 of 9 4.2 DOSE AND METHOD OF ADMINISTRATION DOSE ADULTS : HYPERTENSION: A starting dose of 80 mg twice a day may be increased at weekly intervals according to response. The usual dose range is 160-320 mg per day. With concurrent diuretic or other anti-hypertensive drugs a further reduction of blood pressure is obtained. ANGINA, ANXIETY, MIGR Belgenin tamamını okuyun